These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23290327)

  • 1. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
    Papakostas GI; Vitolo OV; Ishak WW; Rapaport MH; Zajecka JM; Kinrys G; Mischoulon D; Lipkin SH; Hails KA; Abrams J; Ward SG; Meisner A; Schoenfeld DA; Shelton RC; Winokur A; Okasha MS; Bari MA; Fava M
    J Clin Psychiatry; 2012 Dec; 73(12):1541-7. PubMed ID: 23290327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.
    Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; DiPierro M; Cardoos A; Papakostas GI
    Int Clin Psychopharmacol; 2014 Nov; 29(6):332-8. PubMed ID: 24815673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
    Heo JY; Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; Pisoni A; Papakostas GI
    J Psychiatr Res; 2015 Mar; 62():56-61. PubMed ID: 25659187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
    Patkar A; Gilmer W; Pae CU; Vöhringer PA; Ziffra M; Pirok E; Mulligan M; Filkowski MM; Whitham EA; Holtzman NS; Thommi SB; Logvinenko T; Loebel A; Masand P; Ghaemi SN
    PLoS One; 2012; 7(4):e34757. PubMed ID: 22545088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.
    Pascual JC; Soler J; Puigdemont D; Pérez-Egea R; Tiana T; Alvarez E; Pérez V
    J Clin Psychiatry; 2008 Apr; 69(4):603-8. PubMed ID: 18251623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
    Keck PE; Reeves KR; Harrigan EP;
    J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
    Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
    J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
    Mischoulon D; Shelton RC; Baer L; Bobo WV; Curren L; Fava M; Papakostas GI
    J Clin Psychiatry; 2017 Apr; 78(4):449-455. PubMed ID: 27835715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
    J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
    Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
    Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.